



Five Prime Therapeutics, Inc.  
Investor Relations Department  
Two Corporate Dr, Suite 200  
South San Francisco, CA 94080  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

#### NASDAQ: FPRX <sup>1</sup>

Last Trade:	30.73
Trade Time:	4:00 PM ET Wednesday, July 26, 2017
Change:	0.51  (1.688%)
Day Range	30.14 - 31.24
52-Week Range	26.65 - 60.98
Volume	222,230
Market Cap. (\$M)	884.717
Shares Out (M)	28.790

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Wednesday, July 26, 2017*

[Five Prime Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8](#)

*Monday, July 17, 2017*

[Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development](#)

*Wednesday, June 21, 2017*

[Five Prime Therapeutics Announces Lewis T. "Rusty" Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018](#)

*Monday, June 5, 2017*

[Five Prime Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference](#)

*Sunday, June 4, 2017*

[Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis \(PVNS\) at 2017 ASCO Annual Meeting](#)

## Events [\[ View all \]](#)

*Tuesday, August 8, 2017 4:30 PM ET*

[Five Prime Therapeutics, Inc. 2017 Q2 Quarterly Earnings Call](#)

## Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

*Friday, February 24, 2017*  
[Annual Report \(10-K\)](#)

*Friday, March 31, 2017*  
[Definitive Proxy Statement](#)

*Friday, May 5, 2017*  
[Quarterly Report \(10-Q\)](#)

*Friday, November 4, 2016*  
[Quarterly Report \(10-Q\)](#)

*Friday, August 5, 2016*  
[Quarterly Report \(10-Q\)](#)